

---

# Table of Contents

## Section I: General Information

|           |  |    |
|-----------|--|----|
| Chapter 1 | Introduction to International Regulatory Affairs .....                     | 1  |
|           | <i>Updated by Rajaram Balasubramanian, RAC, and Sharad Mi Shukla, RAC</i>  |    |
| Chapter 2 | Crisis Management for the Healthcare Product Industry .....                | 7  |
|           | <i>Updated by Treena Jackson, MS-QA/RA, MA, CQA, RAC, CSSGB</i>            |    |
| Chapter 3 | Clinical Trials, Good Clinical Practice, Regulations and Compliance .....  | 13 |
|           | <i>Updated by Anu Gaur, PhD, MBA, MSRA, RAC</i>                            |    |
| Chapter 4 | In-Country Representation .....  | 25 |
|           | <i>Updated by Pei-Ting Chou, RAC, and Maria Connolly, MPharm</i>           |    |
| Chapter 5 | International Advertising and Promotion .....                              | 41 |
|           | <i>Revised by Treena Jackson, MS-QA/RA, MA, CQA, RAC, CSSGB</i>            |    |
| Chapter 6 | Compliance and Enforcement.....  | 49 |
|           | <i>Updated by Robert Rogers, MS, RAC</i>                                   |    |
| Chapter 7 | International Counterfeit Regulation .....                                 | 63 |
|           | <i>Updated by Vicky Gilles Daniel Verna, MS, BME, MPharm, RAC (Global)</i> |    |

## Section II: Pharmaceuticals

|            |  |     |
|------------|--|-----|
| Chapter 8  | Premarket Requirements/Dossier Requirements.....                               | 83  |
|            | <i>Updated by Monique Carter, MS, RAC, and Jesshanie Tabaniag</i>              |     |
| Chapter 9  | Authorization Procedures for Pharmaceutical Products .....                     | 91  |
|            | <i>By Orin Chisholm, GCULT, PhD, MTOPRA, and Monique Carter MS, RAC</i>        |     |
| Chapter 10 | Stability Test Requirements .....  | 109 |
|            | <i>By Sharry Arora, MPharm, and Rosie Dawes</i>                                |     |
| Chapter 11 | Quality Systems and Inspectorate Process for Pharmaceuticals .....             | 121 |
|            | <i>Updated by Siegfried Schmitt, PhD, CSci, CChem, FRSC</i>                    |     |
| Chapter 12 | Generic Drug Products .....  | 137 |
|            | <i>Updated by Pallavi Trivedi, MPH, RAC, and Anu Gaur, PhD, MBA, MSRA, RAC</i> |     |
| Chapter 13 | Over-the-Counter (OTC) Products.....   | 151 |
|            | <i>Updated by Robert Falcone, PhD</i>  |     |
| Chapter 14 | Pharmaceutical Postmarketing and Compliance.....                               | 159 |
|            | <i>Updated by Valencia Hood-Humphrey, MSRA, and Kathrin Schalper, PhD, RAC</i> |     |

### **Section III: Medical Devices**

|            |   |     |
|------------|---|-----|
| Chapter 15 | Medical Device Premarket Requirements .....   | 175 |
|            | <i>Updated by Amina Abdal, MS, MBA</i>  |     |
| Chapter 16 | Technical and Regulatory Requirements.....  | 193 |
|            | <i>Updated by Robin Stephens and Echo (Yuanyuan) Yu, MS, RAC</i>                                      |     |
| Chapter 17 | Device Quality Systems.....   | 201 |
|            | <i>Updated by Sharad Mi. Shukla, RAC, and Rajaram Balasubramanian, RAC</i>                            |     |
| Chapter 18 | In Vitro Diagnostic Medical Devices.....  | 211 |
|            | <i>Updated by Gert Bos, PhD, FRAPS, and Jocelyn Jennings, MS, RAC</i>                                 |     |
| Chapter 19 | Active Implantable Medical Devices .....  | 231 |
|            | <i>By Gert Bos, PhD, FRAPS</i>  |     |
| Chapter 20 | Software .....  | 241 |
|            | <i>Updated by Echo (Yuanyuan) Yu, MS, RAC, and Raajdeep (Raaj) Venkatesan, MS (EE BME, MDDE), RAC</i> |     |
| Chapter 21 | Postmarket Requirements.....  | 253 |
|            | <i>Updated by Pei-Ting S. Chou, RAC</i>   |     |

### **Section IV: Biologics**

|            |   |     |
|------------|---|-----|
| Chapter 22 | High-Risk Products: Products Derived from Biotechnology.....                | 263 |
|            | <i>Updated by Jocelyn Jennings, MS, RAC, and Angela L. Nelson, MBA, RAC</i> |     |
| Chapter 23 | Biosimilars: Basics and Recent Developments .....                           | 279 |
|            | <i>Updated by Pallavi Trivedi, MPH, RAC</i>                                 |     |
| Chapter 24 | Vaccines .....  | 311 |
|            | <i>By Nicole Beard, MSc, PhD</i>  |     |

### **Section V: Other Product Classifications**

|            |  |     |
|------------|--|-----|
| Chapter 25 | Products Manufactured From Human Blood and Plasma.....   | 329 |
|            | <i>Updated by Indraneel Dasari, RAC</i>  |     |
| Chapter 26 | Principles of Rare Diseases and Orphan Products Development.....                                     | 349 |
|            | <i>Updated by Todd J. Banks, PharmD, RPh, Mridula Shukla, MS, RAC, and Phu Bo Chung, JD, MS, RAC</i> |     |
| Chapter 27 | Combination Products.....  | 359 |
|            | <i>By Deanna Hughes, MS, RAC, and Beat U. Steffen, MSc, MBA</i>                                      |     |
| Chapter 28 | Regulatory Considerations for Cell-Based Medicinal Products .....                                    | 371 |
|            | <i>By Indraneel Dasari, RAC</i>  |     |
| Chapter 29 | Food Supplements and Food for Special Medical Purposes.....  | 385 |
|            | <i>By Irena Medarevic-Milobratovic, MPharm, RAC</i>  |     |
| Chapter 30 | Botanical Drug Products and Traditional Medicine.....  | 399 |
|            | <i>Updated by Irena Medarevic-Milobratovic, MPharm, RAC, and Robert Falcone, PhD</i>                 |     |
| Chapter 31 | Global Pediatric Drug Development .....  | 417 |
|            | <i>By Lynne Georgopoulos, RN, MSHS, RAC, and Daniela Drago, PhD, RAC</i>                             |     |

## Appendices

|  |     |
|--|-----|
| Comparative Matrix of Regulations Across Product Lines ..... | 437 |
| Glossary .....   | 463 |
| Index .....  | 479 |

## Annexes

|   |     |
|---|-----|
| Annex 23-1. US Biosimilar Guidelines .....  | 283 |
| Annex 23-2. Brazil Technical Guidelines, Coordination of Biological Products (CPBIH) and ANVISA ..... | 285 |
| Annex 23-3. EU Product-Specific Biosimilar Guidelines .....   | 286 |

## Figures

|  |     |
|--|-----|
| Figure 3-1. Acceptance of Foreign Clinical Data .....  | 17  |
| Figure 3-2. Quality Management System .....  | 21  |
| Figure 6-1. The Inspection Process Related to Marketing Authorization Applications .....   | 52  |
| Figure 6-2. GxP Guidances Applicable to the Drug Lifecycle .....   | 53  |
| Figure 7-1. An Example of the Common Logo Online Retailers of Medicines Must Displaya .....  | 74  |
| Figure 7-2. Flowchart Representing Product and Information Flow With Unique Product Identifiers and Accompanying Verification and Repository Systemsa .....  | 75  |
| Figure 8-1. CTD Organization .....   | 85  |
| Figure 11-1. Drug Lifecycle Regulations .....  | 122 |
| Figure 11-2. Assessors and Inspectors .....  | 123 |
| Figure 11-3. EU Legal Instruments .....  | 124 |
| Figure 11-4. Inspections as Part of the Drug Approval Process .....  | 125 |
| Figure 14-1. MedDRA Coding Hierarchy .....   | 169 |
| Figure 15-1. Decision Tree for Noninvasive Device Classification .....   | 186 |
| Figure 15-2. Decision Trees for Invasive Device Classification .....   | 187 |
| Figure 15-3. Decision Tree 2 for Invasive Devices .....  | 188 |
| Figure 15-4. Decision Tree 1 for Active Device Classification .....  | 189 |
| Figure 15-5. Decision Tree 2 for Active Device Classification .....  | 190 |
| Figure 15-6. Decision Tree for Device Classification With Additional Rules .....   | 191 |
| Figure 16-1. Premarket Use of the STED .....   | 195 |
| Figure 16-2. Postmarket Use of the STED .....  | 196 |
| Figure 17-1. Influence of Design Controls on the Design Process .....  | 204 |
| Figure 17-2. Process Validation Decision Tree .....  | 206 |
| Figure 17-3. Key Activities for Supplier Control .....   | 207 |
| Figure 18-1. General GHTF Classification System for IVD Medical Devices .....  | 213 |
| Figure 18-2. Regulatory Requirements Related to the Device Risk Class .....  | 213 |
| Figure 20-1. MDD Decision Tree .....   | 244 |
| Figure 20-2. IVDD Decision Tree .....  | 246 |
| Figure 23-1. Influence of Stakeholders as Drivers of Biosimilars .....   | 282 |
| Figure 23-2. Standalone vs. Abbreviated Development Programs .....   | 291 |
| Figure 23-3. Regulation in Latin America .....   | 307 |
| Figure 23-4. Middle Eastern Market Growth of Pharmaceuticals .....   | 308 |
| Figure 24-1. OCABR Decision Flowchart (Extracted from EU Administrative Procedure for Official Control Authority Batch Release—Human Vaccine and Blood Derived Medicinal Products) (June 2016) ..... | 320 |
| Figure 24-2. Process of Influenza Vaccine Virus Selection and Development .....  | 323 |
| Figure 25-1. Overview of Blood Product Manufacturing Process .....   | 334 |
| Figure 25-2. Approaches to be Employed During Blood Product Processing .....   | 339 |
| Figure 28-1. Cell Therapy Product Sources and ATMP Manufacturing Process Overview .....  | 373 |
| Figure 28-2. Indications of Advanced Therapy Trials .....  | 374 |
| Figure 28-3. ATMP Process Development Framework .....  | 376 |
| Figure 28-4. Overview ATMP Approval Centers in the US, EU and Japan .....  | 377 |
| Figure 28-5. Overview of Challenges Industry and Stakeholders Face in ATMP Development and Commercialization .....   | 383 |
| Figure 30-1. US Regulatory Pathways for Marketing Botanical Drug Products .....  | 405 |
| Figure 30-2. Information Needed in an IND for a Botanical Drug Product .....   | 410 |
| Figure 31-1. Overview of the iPSP Process .....  | 423 |
| Figure 31-2. Overview of the PIP Procedure .....   | 428 |

## Tables

|              |   |     |
|--------------|---|-----|
| Table 3-1.   | Regional Regulatory Authorities.....  | 18  |
| Table 3-2.   | Trial Master File Essential Documents .....   | 23  |
| Table 7-1.   | Definitions of Key Terms in This Chaptera .....   | 65  |
| Table 7-2.   | DSCSA Definition of Stakeholders and Key Terminology.....   | 66  |
| Table 7-3.   | Timelines for Implementation of Key Plan Elements .....   | 67  |
| Table 7-4.   | Different Medicinal Product Supply Chain Stakeholder Requirements Under the FMDa .....                                | 72  |
| Table 7-5.   | Persons or Institutions That May Be Considered Exempt by Individual Statesa.....                                      | 73  |
| Table 7-6.   | List and Status of Third Countries Requested to be Listed .....   | 76  |
| Table 8-1.   | ACTD Format and Content .....   | 89  |
| Table 9-1.   | Country-Specific Regulatory Requirements.....   | 93  |
| Table 10-1.  | Climatic Zones .....  | 110 |
| Table 10-2.  | WHO Recommended Stability Testing Conditions for Drug Substance and Drug Product .....                                | 112 |
| Table 10-3.  | Recommended Stability Storage Conditions for Refrigerated and Frozen Drug Substance and Drug Product .....            | 113 |
| Table 10-4.  | Country-Specific Climatic Zones and Stability Data Requirements for Asia Pacific Region.....                          | 116 |
| Table 10-5.  | Country-Specific Climatic Zones and Stability Data Requirements for Latin America .....                               | 117 |
| Table 10-6.  | Country-Specific Climatic Zones and Stability Data Requirements for SEE, Middle East and Africa.....                  | 118 |
| Table 11-1.  | PIC/S Member States.....  | 132 |
| Table 12-1.  | Comparison of Generic Product Development Regulatory Requirements in Select Countries.....                            | 139 |
| Table 12-2.  | Comparative Study Parameter Assessment Between the US, EU and Canada .....  | 143 |
| Table 14-1.  | MAH Reporting Requirements.....   | 170 |
| Table 15-1.  | Class A Device .....  | 179 |
| Table 15-2.  | Class B Device .....  | 180 |
| Table 15-3.  | Class C Device.....   | 180 |
| Table 15-4.  | Class D Device.....   | 181 |
| Table 15-5.  | Noninvasive Devices .....   | 181 |
| Table 15-6.  | Invasive Devices .....  | 182 |
| Table 15-7.  | Active Devices .....  | 184 |
| Table 15-8.  | Additional Rules .....  | 185 |
| Table 18-1.  | Classification Rules for IVDs .....   | 214 |
| Table 18-2.  | Classification Rules for IVDs .....   | 215 |
| Table 18-3.  | Class A Device .....  | 216 |
| Table 18-4.  | Class B Device .....  | 216 |
| Table 18-5.  | Class C Device.....   | 217 |
| Table 18-6.  | Australian Classification Scheme .....  | 225 |
| Table 18-7.  | Conformity Assessment Stages .....  | 227 |
| Table 18-8.  | Rule 9 Special Classification.....  | 228 |
| Table 20-1.  | Examples of Software Types and Their EU Qualification as General Medical Devices .....                                | 250 |
| Table 22-1.  | Comparison of ICH CTD and ASEAN CTD Structures.....   | 274 |
| Table 23-1.  | Advantages and Disadvantages of Equivalence/Noninferiority Designs for SBPs .....                                     | 283 |
| Table 23-2.  | EMA Biosimilar Marketing Approvals via the Centralised Procedure .....  | 284 |
| Table 23-3.  | Typical Biosimilar Product Marketing Application Dossiers and Data Requirement for Approval in the EU.....            | 287 |
| Table 23-4.  | FDA Approved Biosimilars Listed in Purple Book (30 August 2016) .....   | 290 |
| Table 23-5.  | Typical Dossier and Data Requirements for US Biosimilar Applications .....  | 292 |
| Table 23-6.  | PMDA-Approved Biosimilars as of March 2016 .....  | 294 |
| Table 23-7.  | Typical Dossier and Data Requirements for Biosimilar Applications in Japan.....                                       | 296 |
| Table 23-8.  | Typical Application Dossier and Data Requirements for Biosimilar Marketing Applications and Approvals in India...298  |     |
| Table 23-9.  | Typical Application Dossier and Data Requirement for Biosimilar Marketing Applications and Approvals in China...300   |     |
| Table 23-10. | MFDS-Approved Biosimilars .....   | 301 |
| Table 23-11. | Typical Application Dossier and Data Requirements for Biosimilar Marketing Applications and Approvals in Korea ...302 |     |
| Table 23-12. | Rest of Asia Pacific .....  | 305 |
| Table 23-13. | Typical Application Dossier and Data Requirements for Biosimilar Marketing Applications and Approvals in Brazil ..... | 306 |
| Table 24-1.  | Adjuvants Licensed in the EU .....  | 322 |
| Table 24-2.  | European Guidelines for Influenza Vaccines.....   | 324 |
| Table 25-1.  | Overview of Products Manufactured From Blood and Their Clinical Significance.....                                     | 331 |
| Table 25-2.  | Overview of Blood Product Approvals Obtained in the US.....   | 332 |

|             |  |     |
|-------------|--|-----|
| Table 25-3. | Evidence of Infection Transmission by Human Blood .....                          | 336 |
| Table 26-1. | Overview of Orphan Drug Framework .....  | 352 |
| Table 27-1. | Examples of FDA-Approved Combination Products .....                              | 361 |
| Table 27-2. | Combination Product Categories .....   | 363 |
| Table 27-3. | Applicable Articles When the Medicinal Product is Ancillary .....                | 368 |
| Table 27-4. | Applicable Articles for Devices to Administer Medicinal Products.....            | 369 |
| Table 28-1. | Approved Autologous Human Cells and Tissue Products in the US, EU and Japan..... | 375 |
| Table 28-2. | US, EU and Japan Regulatory Framework Overview .....                             | 376 |
| Table 28-3. | Overview of EU Regulatory Approach .....   | 378 |
| Table 28-4. | Overview of EU Regulatory Approach .....   | 379 |
| Table 28-5. | Overview of Applicable US Regulatory Guidelines.....                             | 380 |
| Table 28-6. | Overview of Applicable EU Regulatory Guidelines .....                            | 381 |
| Table 28-7. | Overview of Applicable Japanese Regulatory Guidelines .....                      | 382 |
| Table 30-1. | Traditional Herbal or Botanical Product Regulations in Selected Countries .....  | 402 |
| Table 30-2. | Direct-to-OTC Criteria for BDPs With Only Non-US Experience .....                | 407 |
| Table 30-3. | Strategic Considerations for Developing a BDP for US Approval.....               | 408 |
| Table 30-4. | Comparison of BDPs and Conventional Drugs.....                                   | 409 |
| Table 31-1. | FDA Pediatric Age Categories for Labeling of Drugs and Biologics .....           | 420 |
| Table 31-2. | Outline of the initial Pediatric Study Plan (iPSP) .....                         | 422 |
| Table 31-3. | Overview of BPCA and PREA .....  | 424 |
| Table 31-4. | Paediatric Regulation—Key Requirements and Incentives .....                      | 426 |
| Table 31-5. | Overview of Information Required in a PIP .....                                  | 430 |